The author is a partner with Fox Rothschild LLP, Lawrenceville, NJ.
To: First Assistant U.S. Attorney; Chief, Securities and Health Care Fraud Unit
From: Alain Leibman, AUSA
Re: Prosecution Memorandum (GyneTech and Michael Bass)
As requested, I’ve preliminarily reviewed the Food and Drug Administration (FDA) Office of Inspector General’s case report in the above matter, met with the lead agent Special Agent (SA) Smith, and mapped out a plan of investigation. My analysis and plan are set forth below.